Pharmacological Ascorbate Elicits Anti-Cancer Activities against Non-Small Cell Lung Cancer through...

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Non-small cell lung cancer (NSCLC) has poor survival rates despite current treatments.
• Novel therapeutic strategies are needed to improve outcomes for NSCLC patients.
• Pharmacological ascorbate (P-AscH^-) is being investigated as a potential anti-cancer agent.

Purpose of the Study:

• To investigate the anti-cancer effects of pharmacological ascorbate (P-AscH^-) on NSCLC.
• To elucidate the underlying mechanisms of P-AscH^-'s anti-cancer activity in NSCLC.
• To explore the role of DNA damage and oxidative stress in P-AscH^-'s efficacy.

Main Methods:

• Treatment of NSCLC cells with pharmacological ascorbate (P-AscH^-).
• Assessment of cellular oxidative stress, bioenergetics, apoptosis, and clonogenic survival.
• Analysis of DNA damage markers and DNA repair machinery localization.
• Evaluation of P-AscH^- effects with and without catalase co-treatment.

Main Results:

• P-AscH^- induced significant oxidative distress and disrupted cellular bioenergetics in NSCLC cells.
• P-AscH^- treatment led to apoptosis, reduced clonogenic survival, and increased DNA damage.
• DNA repair machineries were mislocalized, and DNA damage markers were elevated following P-AscH^- treatment.
• Extracellular hydrogen peroxide was identified as a key mediator of P-AscH^-'s anti-cancer effects, as evidenced by reversal with catalase.

Conclusions:

• Pharmacological ascorbate (P-AscH^-) exhibits potent anti-cancer effects against NSCLC.
• P-AscH^- targets DNA integrity and cellular bioenergetics, leading to cancer cell death.
• The findings support the potential clinical application of P-AscH^- as a novel therapy for NSCLC.